Plasma Phenylacetylglutamine Levels and Prognosis of Ischemic Stroke: A Multicenter Prospective Study Based on the CATIS Trial
- 1 November 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 55 (11) , 2652-2660
Abstract
BACKGROUND: Phenylacetylglutamine is implicated in platelet clotting and thrombosis, but its prognostic value in ischemic stroke remains unclear. We aimed to explore the associations of plasma phenylacetylglutamine levels with adverse outcomes after ischemic stroke in a multicenter prognostic cohort study. METHODS: Our multicenter prognostic cohort study included 3564 Chinese patients with ischemic stroke from the CATIS (China Antihypertensive Trial in Acute Ischemic Stroke). All patients were followed up at 3 months after ischemic stroke onset. The primary outcome was the composite outcome of death or major disability (modified Rankin Scale score, 3–6) at 3 months after ischemic stroke. RESULTS: During 3 months of follow-up, 877 participants experienced the primary outcome. After multivariate adjustment, each 500 ng/mL increase of phenylacetylglutamine was associated with a 7% ( P =0.012), 6% ( P =0.016), and 6% ( P =0.028) increased risk of the primary outcome, major disability, and death, respectively. The odds ratios or hazard ratios in the highest versus the lowest quartile of plasma phenylacetylglutamine were 1.62 ([95% CI, 1.18–2.23]; P trend =0.001) for the primary outcome, 1.62 ([95% CI, 1.16–2.24]; P trend =0.001) for major disability, and 2.59 ([95% CI, 1.19–5.60]; P trend =0.025) for death, respectively. There was a significantly worse shift in the distribution of modified Rankin Scale score at 3 months with higher phenylacetylglutamine quartiles ( P trend =0.003). Multiple-adjusted spline regression model showed a linear relationship between phenylacetylglutamine and primary outcome ( P value for linearityP P =0.019). CONCLUSIONS: Elevated plasma phenylacetylglutamine levels at baseline were associated with increased risks of adverse clinical outcomes at 3 months after ischemic stroke, suggesting that phenylacetylglutamine may be a promising prognostic biomarker for ischemic stroke. Further studies are needed to investigate whether phenylacetylglutamine is a stroke-specific biomarker.Keywords
Funding Information
- The National Natural Science Foundation of China (82220108001 and 82103917)
- Suzhou Science and Technology Project (SKY2023132)
This publication has 25 references indexed in Scilit:
- Phenylacetylglutamine increases the susceptibility of ventricular arrhythmias in heart failure mice by exacerbated activation of the TLR4/AKT/mTOR signaling pathwayInternational Immunopharmacology, 2023
- Primary stroke prevention worldwide: translating evidence into actionThe Lancet Public Health, 2021
- Phenylacetylglutamine is associated with the degree of coronary atherosclerotic severity assessed by coronary computed tomographic angiography in patients with suspected coronary artery diseaseAtherosclerosis, 2021
- Butyrate-producing bacteria and the gut-heart axis in atherosclerosisClinica Chimica Acta, 2020
- A Cardiovascular Disease-Linked Gut Microbial Metabolite Acts via Adrenergic ReceptorsCell, 2020
- Association of platelet-to-lymphocyte ratio with silent brain infarcts in patients with paroxysmal atrial fibrillationNeurological Research, 2016
- Effects of Immediate Blood Pressure Reduction on Death and Major Disability in Patients With Acute Ischemic StrokeJAMA, 2014
- Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyondStatistics in Medicine, 2007
- Flexible regression models with cubic splinesStatistics in Medicine, 1989
- SYNTHESIS OF PHENYLACETYLGLUTAMINE BY HUMAN TISSUEJournal of Biological Chemistry, 1957